Home > Healthcare > Medical Devices > Diagnostic Devices > Cancer Diagnostics Market

Cancer Diagnostics Market Size

Report ID: GMI2406
Published Date: Jan 2023
Report Format: PDF

Download Free Sample

Cancer Diagnostics Market Size

Cancer Diagnostics Market size was worth more than USD 136 billion in 2022 and is projected to exhibit over 9% CAGR from 2023-2032. Rising prevalence of cancer across the globe will accelerate industry growth.

To get key market trends

Download Free Sample

The growing incidences of cancer driven by the adoption of unhealthy dietary habits and sedentary lifestyles is expected to influence the cancer diagnostics market outlook. Several initiatives, funding, and private-public partnerships established to boost cancer research and improve access to advanced screening services will pave the way for enhanced industry growth. For instance, in August 2022, the National Cancer Grid (NCG) of India unveiled a new digital oncology center to promote the use of digital technologies in cancer care.

The ongoing advancements in the field of next-generation cancer diagnostics are allowing early detection of cancerous cells using AI and an array of digital tools. For instance, in December 2022, Ibex Medical Analytics announced the deployment of its AI-based cancer diagnostic solution, Galen™ Prostate at the University of Pittsburgh Medical Center (UPMC) network.

Cancer Diagnostics Market Report Attributes
Report Attribute	Details
Base Year:	2022
Cancer Diagnostics Market Size in 2022:	USD 136 Billion
Forecast Period:	2023 to 2032
Forecast Period 2023 to 2032 CAGR:	9%
2032 Value Projection:	USD 324 Billion
Historical Data for:	2018 to 2032
No. of Pages:	300
Tables, Charts & Figures:	274
Segments covered:	Application, Cancer Type, End-use and Region
Growth Drivers:	Rising incidence of cancer globally Several initiatives undertaken by government and other organizations to spread disease awareness Growing number of diagnostic laboratories in developed countries Technological advancements in developed countries
Pitfalls & Challenges:	High capital investment coupled with high cost associated with diagnostic imaging system Risk related with high radiation exposure affecting use of CT scanner

Learn more about the key segments shaping this market

Download Free Sample

Increasing health concerns associated with radiation exposure could hamper industry outlook

The extensive usage of CT scanners in cancer diagnostics and screening is linked with high radiation exposure as compared to conventional technologies, leading to limited demand for modern radiation therapies. Patients exposed to a radiation dose of 40 mSv, equivalent to four-phase abdominal CT scanning are at a higher risk of developing different types of tumors. As a result, multiple regulatory agencies such as the U.S. FDA and the European Commission are deploying strict guidelines and regulations pertaining to adequate radiation dosage to ensure public health safety.

Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

Global market for cancer diagnostics was worth more than USD 136 billion in 2022 and is projected to exhibit over 9% CAGR from 2023-2032.

Non-Hodgkin lymphoma (NHL) is estimated to reach over USD 18.5 billion by 2032 due to increasing prevalence in the aging population.

Europe cancer diagnostics market size is slated to surpass USD 93.5 billion by 2032 owing to the presence of growing healthcare expenditure and supportive initiatives.

Abbott Laboratories, BioMerieux SA, Biocartis, Hologic Inc, Qiagen N.V, Myriad Genetics, Inc, and Sysmex Corporation are some key participants in the market.